Related Experiment Video
Updated: Jul 17, 2026

Combined Near-infrared Fluorescent Imaging and Micro-computed Tomography for Directly Visualizing Cerebral Thromboemboli
Published on: September 25, 2016
Cerebral Venous Thrombosis in COVID-19: A New York Metropolitan Cohort Study
F Al-Mufti1,2, K Amuluru3, R Sahni4,2
1From the Departments of Neurosurgery (F.A.-M., R.S., J.C., P.O., R.N., J.F.D., T.S., E.G., S.A.M., C.G.) Fawaz.Al-Mufti@wmchealth.org.
Insights
Patients hospitalized with COVID-19 showed a higher incidence of cerebral venous thrombosis (CVT). CVT should be considered in patients with COVID-19 presenting with neurological symptoms.
Area of Science:
- Neurology
- Infectious Diseases
- Vascular Medicine
Background:
- Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection is linked to hypercoagulability.
- COVID-19 patients exhibit an increased risk for thrombotic events.
Purpose of the Study:
- To evaluate the demographic and clinical characteristics of cerebral venous thrombosis (CVT) in hospitalized COVID-19 patients.
- To determine the incidence of CVT in a large cohort of COVID-19 patients.
Main Methods:
- Retrospective multicenter cohort study.
- Inclusion of 13,500 consecutive patients hospitalized with COVID-19.
- Data collection from March 1 to May 30, 2020, across 6 tertiary care centers.
Main Results:
- Twelve patients (0.09%) were diagnosed with imaging-proved CVT, an incidence of 8.8 per 10,000 over 3 months.
- This incidence is significantly higher than the general population's annual incidence (5 per million).
- Neurologic symptoms preceded CVT diagnosis in 58% of cases; 75% had venous infarction or hemorrhage.
Conclusions:
- Hospitalized COVID-19 patients demonstrate a higher-than-expected frequency of cerebral venous thrombosis.
- Cerebral venous thrombosis should be considered in the differential diagnosis for neurologic syndromes in SARS-CoV-2 infected individuals.
Background And Purpose:
Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection is associated with hypercoagulability. We sought to evaluate the demographic and clinical characteristics of cerebral venous thrombosis among patients hospitalized for coronavirus disease 2019 (COVID-19) at 6 tertiary care centers in the New York City metropolitan area.
Materials And Methods:
We conducted a retrospective multicenter cohort study of 13,500 consecutive patients with COVID-19 who were hospitalized between March 1 and May 30, 2020.
Results:
Of 13,500 patients with COVID-19, twelve had imaging-proved cerebral venous thrombosis with an incidence of 8.8 per 10,000 during 3 months, which is considerably higher than the reported incidence of cerebral venous thrombosis in the general population of 5 per million annually. There was a male preponderance (8 men, 4 women) and an average age of 49 years (95% CI, 36-62 years; range, 17-95 years). Only 1 patient (8%) had a history of thromboembolic disease. Neurologic symptoms secondary to cerebral venous thrombosis occurred within 24 hours of the onset of the respiratory and constitutional symptoms in 58% of cases, and 75% had venous infarction, hemorrhage, or both on brain imaging. Management consisted of anticoagulation, endovascular thrombectomy, and surgical hematoma evacuation. The mortality rate was 25%.
Conclusions:
Early evidence suggests a higher-than-expected frequency of cerebral venous thrombosis among patients hospitalized for COVID-19. Cerebral venous thrombosis should be included in the differential diagnosis of neurologic syndromes associated with SARS-CoV-2 infection.
More Related Videos
08:12A Volumetric Method for Quantification of Cerebral Vasospasm in a Murine Model of Subarachnoid Hemorrhage
Published on: July 28, 2018
10:41Analysis of Cerebral Vasospasm in a Murine Model of Subarachnoid Hemorrhage with High Frequency Transcranial Duplex Ultrasound
Published on: June 3, 2021
Related Concept Videos
Venous Thrombosis I: Introduction
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Arboviral Encephalitis
Cryptococcal Meningitis
Hemorrhagic Stroke ll: Pathophysiology
Cerebral Edema ll: Pathophysiology